Scandinavian Journal of Immunology最新文献

{"title":"Multiparametric Optimization of Human Primary B-Cell Cultures Using Design of Experiments.","authors":"Anne Bruun Rovsing, Kenneth Green, Lisbeth Jensen, Ian Helstrup Nielsen, Jacob Giehm Mikkelsen, Søren E Degn","doi":"10.1111/sji.70043","DOIUrl":"10.1111/sji.70043","url":null,"abstract":"<p><p>B cells are essential in the immune system, driving antibody production, cytokine secretion and antigen presentation. Studies in mouse models have illuminated key mechanisms underlying B-cell activation, differentiation, class-switch recombination and somatic hypermutation. However, the extent to which these findings translate to human biology remains unclear. To address this, we developed a human primary B-cell culture system using feeder cells engineered to express CD40L, supplemented with the cytokines BAFF, IL-4 and IL-21. Using a Design of Experiments (DOE) approach, we optimised critical parameters and dissected the individual contributions of each specific factor. Our results reveal that BAFF plays a negligible role, and IL-21 has more subtle effects, whereas CD40L and IL-4 are critical determinants of cell viability, proliferation and IgE class-switching. Furthermore, we find that engineered feeder cells can serve equally well as a source of cytokines, but providing these in purified form increases the flexibility of the system. This platform enables detailed investigation of human B-cell biology, offering insights into intrinsic and extrinsic regulators of antibody responses and providing a foundation for in vitro production of human primary antibodies.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"102 2","pages":"e70043"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefining the Immunobiology of Organ Transplantation for New Clinical Horizons.","authors":"Masoud H Manjili","doi":"10.1111/sji.70045","DOIUrl":"10.1111/sji.70045","url":null,"abstract":"<p><p>Traditional organ transplantation relies on the Self-Non-self (SNS) model of immunity, focusing on donor-recipient compatibility and aggressive immunosuppression to prevent acute rejection. Although effective early, this strategy does not prevent chronic rejection and cannot account for operational tolerance, failure of perfectly HLA-matched grafts, or the occasional spontaneous acceptance of a fully mismatched organ. The adaptation model of immunity offers a different lens. In the thymus, \"central adaptation\" programs T cells to recognise self-peptide-MHC (pMHC) so they can later recognise different tissues to facilitate tissue repair and homeostasis. Whether a graft thrives or fails depends on how quickly this self-oriented circuitry can operate. Autografts and isografts arrive with their own extracellular-matrix (ECM) \"memory\", and recipient T cells immediately recognise their pMHC, triggering tissue-remodelling responses. Allografts must adapt to new ECM-a transition that is associated higher levels of graft injury allowing indirect antigen presentation. Until adaptation is complete, recipient T cells mount cytotoxic rather than reparative responses because of antigen cross-presentation, during which the graft relies on donor-derived tissue-resident memory T cells (T_RM) to maintain integrity. Therapeutically, interventions that preserve or expand graft-borne T_RM, or that pharmacologically enhance adaptation-receptor signalling, could hasten this donor-to-host reprogramming. By replacing blanket immunosuppression with targeted promotion of tissue-remodelling immunity, the adaptation model charts a path toward long-term graft survival without the lifelong risks of today's regimens.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"102 2","pages":"e70045"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-Activating Factor Promotes Neutrophil Activation and Platelet-Neutrophil Complex Formation.","authors":"Lisa Wohlgemuth, Christiane Leonie Knapp, Laura Vidoni, Stefan Hug, Paul Müller, Adam Omar Khalaf Mohamed, Annika Dietz, Alexander Elias Paul Stratmann, Laura Stukan, Larissa Melina Höpfer, Bertram Dietrich Thomaß, Alexander Sebastian Koller, Frederik Münnich, Michael Ruhland, Markus Huber-Lang, David Alexander Christian Messerer","doi":"10.1111/sji.70044","DOIUrl":"10.1111/sji.70044","url":null,"abstract":"<p><p>Controlling excessive inflammation remains an unmet clinical need, for example, during sepsis or after severe injuries. Platelet-activating factor (PAF) is central in thromboinflammatory processes. However, its role in the interaction of platelets and neutrophils requires further insights. Therefore, we elucidated PAF-related neutrophil activation, including platelet-neutrophil complex (PNC) formation and investigated potential strategies to modulate PAF-related inflammation. For the translation of the PAF-mediated inflammation, we applied an animal-free human ex vivo whole blood model. The neutrophil phenotype, its function, and PNC formation were studied by flow cytometry and platelet-related activity was assessed by light microscopy and aggregometry. PAF induced a rapid and dose-dependent change in neutrophil phenotype, as evidenced by CD10, CD11b, and CD66b upregulation and CD62L downregulation. Moreover, PAF increased the generation of reactive oxygen species (ROS), phagocytic activity and PNC formation. Interestingly, PNCs displayed significantly enhanced ROS formation and phagocytosis compared to neutrophils without attached platelets, whereas these differences were not observed regarding phenotype changes. Furthermore, the findings were confirmed in a clinically relevant ex vivo whole blood model of lipopolysaccharide- or PAF-driven inflammation. In summary, the present study elucidates PAF-driven effects on neutrophils and their interaction with platelets. The findings might help in developing therapeutic approaches to modulate PAF-related thromboinflammation, for example, during sepsis.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"102 2","pages":"e70044"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TCF3 and ID3 Regulate TSPAN32 Expression in Burkitt Lymphoma.","authors":"Grazia Scuderi, Katia Mangano, Gian Marco Leone, Paolo Fagone, Ferdinando Nicoletti","doi":"10.1111/sji.70040","DOIUrl":"10.1111/sji.70040","url":null,"abstract":"<p><p>Burkitt lymphoma (BL) is an aggressive non-Hodgkin B-cell lymphoma characterised by chromosomal translocations involving the MYC gene, leading to its overexpression and driving uncontrolled proliferation. BL is categorised into endemic, sporadic, and immunodeficiency-associated subtypes, each with distinct clinical and epidemiological features. TSPAN32, a member of the tetraspanin family, plays a key role in B cell development and immune regulation. In this study, we investigated the regulation of TSPAN32 expression in BL subtypes. Our results show that TSPAN32 expression is significantly downregulated in endemic, sporadic, and HIV-associated BL. Notably, this downregulation is independent of Epstein-Barr virus (EBV) infection, as no significant differences in TSPAN32 expression were observed between EBV-positive and EBV-negative BL clones. Functional studies revealed that overexpression of a wild-type ID3 gene, a known repressor of TCF3, and knockdown of TCF3, both led to a significant upregulation of TSPAN32, particularly in BL41 and Daudi cells, which harbour ID3 mutations. Supporting this, ChIP-seq analysis identified TCF3 binding peaks on the TSPAN32 gene, providing mechanistic evidence of its regulation by TCF3. These findings shed light on the complex transcriptional network regulating TSPAN32 and its dysregulation in BL. Overall, our study suggests that TSPAN32 may serve as both a biomarker and a potential therapeutic target for this disease.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"102 1","pages":"e70040"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144508021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Study of CD10^low Polymorphonuclear Leukocytes Preceding and Correlating With Postsurgical Inflammation.","authors":"Timo Michael Westermann, Joe Sendas, Alexander Sebastian Koller, Darko Jovanovski, Dominik Hüsken, Pascal Max Lucien Lessing, Birte Weber, Bernd Mühling, Andreas Liebold, David Alexander Christian Messerer, Markus Huber-Lang, Lisa Wohlgemuth","doi":"10.1111/sji.70042","DOIUrl":"10.1111/sji.70042","url":null,"abstract":"<p><p>The lack of diagnostic and monitoring tools for postsurgical immunological complications such as systemic inflammation can contribute to a poor outcome despite modern intensive care. The need for reliable immune monitoring has been emphasised. Polymorphonuclear leukocytes (PMNs) play an important role in postsurgical inflammation. A subgroup of PMNs is particularly interesting, because they are released shortly after (iatrogenic) trauma: immature PMNs, characterised by, for example, their low CD10 expression. Therefore, we investigated the role of CD10^low PMNs in a non-interventional exploratory study by including patients undergoing scheduled, highly standardised cardiac surgery with extracorporeal circulation. We were able to demonstrate that the number of CD10^low PMNs released shortly after the beginning of surgery correlated with different fluid phase markers of inflammation and organ damage postsurgically. Among these parameters were CRP, IL-6, NGAL, CK-MB, and troponin-T. Noteworthy, the amount of CD10^low PMNs increased as early as 24 h before these well-established markers, suggesting superiority of CD10^low PMNs as an early diagnostic marker. Comparing CD10^low immature PMNs with CD10^high mature PMNs revealed potential involved mechanisms, including lower CD11b expression and a significant decrease in the formation of platelet-neutrophil complexes (PNCs) by CD10^low PMNs. In conclusion, we propose CD10^low PMNs as a potential early cellular biomarker to assess the postsurgical inflammatory response. In comparison to clinically established markers like CRP or IL-6 and scoring systems such as the SOFA-Score, CD10^low PMNs reflect a potential candidate for future immune monitoring to determine the risk of excessive inflammation and organ impairment more rapidly.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"102 1","pages":"e70042"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Well-Controlled Mucosal Exudation of Undiluted Plasma Proteins Serves Innate and Adaptive Immunity.","authors":"Carl Persson","doi":"10.1111/sji.70041","DOIUrl":"10.1111/sji.70041","url":null,"abstract":"<p><p>Distinct from the pulmonary circulation, the human respiratory mucosa is supplied by highly responsive, superficial, systemic microcirculations. In the early symptomatic phase of mucosal infections, circulating peptides-proteins of all sizes are released just beneath the epithelium and will soon appear on the mucosal surface. The traditional view is that mucosal injury must be involved in this plasma exudation process. However, well-controlled human in vivo observations demonstrate that the inflammatory plasma exudation response reflects non-injurious physiologic microvascular-epithelial cooperation. Crucially, although plasma exudation brings unfiltered plasma solutes without size restriction to the mucosal surface this occurs without reducing the protective epithelial barrier against inhaled molecules. Plasma exudation starts early and increases until viral or bacterial infections resolve. Plasma exudation therefore has the potential to slow down, or even prevent, progression to pneumonia and beyond. Plasma exudation would boost efficacy of a mature adaptive immunity by delivering circulating pathogen-neutralising antibodies undiluted to infection spots in the upper airways. Early mucosal infections would thus be dampened and development of lower airway infections prevented. Inferentially, this explains how treatment with vaccines still allows upper airway infections but prevent severe respiratory disease with alveolar and pulmonary circulation injury. Plasma exudation may also contribute to real-life protection against severe influenza/Covid-19 in airway mucosal diseases that exhibit plasma exudation hyperresponsiveness. Such hyperresponsiveness is inducible indicating feasibility of finding future treatments that increase the mucosal innate and adaptive immunity. Altogether, the present synthesis of literature suggests that plasma exudation is an important component of human respiratory mucosal antimicrobial immunity.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"102 1","pages":"e70041"},"PeriodicalIF":4.1,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12209697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144529472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EBV and Molecular Mimicry: Therapeutic Implications.","authors":"Guglielmo Lucchese, Angela Stufano","doi":"10.1111/sji.70036","DOIUrl":"https://doi.org/10.1111/sji.70036","url":null,"abstract":"","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"101 6","pages":"e70036"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144275868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percentages of Effector Memory T Cells in Peripheral Blood Associated With Non-Infectious Comorbidities in Common Variable Immunodeficiency Disorders.","authors":"Jesús A Álvarez-Álvarez, Estefanía Vásquez-Echeverri, Isaura P Sánchez, Sebastián Gutierrez Hincapié, Alejandro Gallon Duque, Rubén D Gómez-Arias, Julio C Orrego Arango, José L Franco, Claudia M Trujillo-Vargas","doi":"10.1111/sji.70037","DOIUrl":"10.1111/sji.70037","url":null,"abstract":"<p><p>Common variable immunodeficiency disorders (CVID) are characterized by hypogammaglobulinemia and increased susceptibility to infections. However, non-infectious comorbidities (NICM) are also frequent manifestations of the disease. We search for distinctive immunophenotypes in CVID patients with NICM. Data were obtained from the clinical records and laboratory analyses of 42 CVID patients. Descriptive statistics, median comparisons, bivariate and multivariate analysis were performed. Median comparison of the immunological variables among patients with or without NICM revealed significant decreased levels of serum IgG, percentages of naïve CD4⁺ and CD8⁺ T cells, total B cells and CD56^dim NK cells in peripheral blood from CVID patients with NICM together with an increase in the percentages of effector memory (EM) CD4⁺ and terminally differentiated effector memory (EMRA) CD8⁺ T cells. By using logistic regressions, we determined the likelihood of exhibiting blood immunological abnormalities in patients with NICM vs. those without NICM. Finally, discriminant analyses and ROC curves established that percentages of CD4⁺ EM T cells and CD8⁺ EMRA T cells > 47.4% and 40.2% from the total CD4⁺ or CD8⁺ T cells, respectively, might be associated with NICM in CVID. These differences were also observed in CVID patients with Polyclonal lymphocytic infiltration. These data suggest subpopulations of effector T cells as potential biomarkers of NICM in CVID. Prospective studies are needed to determine the usefulness of our findings in the prognosis of CVID.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"101 6","pages":"e70037"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Primary Immunodeficiency Diagnosis: Findings From Targeted Genetic Testing in a Turkish Cohort.","authors":"Çiğdem Aydoğmus, Sibel Kaplan Sarıkavak, Burcu Cil, Özge Türkyılmaz Uçar, Pinar Gökmirza Özdemir, Serdar Al, Salim Can, Safa Barış, Jessica Quinn","doi":"10.1111/sji.70031","DOIUrl":"https://doi.org/10.1111/sji.70031","url":null,"abstract":"<p><p>Primary immunodeficiency disorders (PIDDs) comprise a heterogeneous group of genetic conditions characterised by recurrent infections, immune dysregulation and increased susceptibility to malignancies. While clinical evaluation remains essential for diagnosis, genetic testing plays a pivotal role in confirming the diagnosis and guiding management. This cross-sectional study evaluates the diagnostic yield and clinical utility of targeted gene panel testing in patients with a strong clinical suspicion of PIDDs, within the framework of the Jeffrey Modell Foundation's 'Jeffrey's Insights' programme. Between 2022 and 2024, 104 patients without a prior genetic diagnosis were evaluated at the Department of Paediatric Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Türkiye. In 72 of 104 patients, the identified variants were consistent with clinical phenotypes. Pathogenic or likely pathogenic variants were identified in 41.3% of patients, increasing to 57.7% when including variants of uncertain significance (VUS) with high CADD scores. Genetic findings prompted reclassification of International Union of Immunological Societies (IUIS) categories in 25% of cases. Autosomal recessive inheritance and parental consanguinity were notable, reflecting regional genetic patterns. Failure to thrive and low switched memory B cell percentages were significantly associated with confirmed genetic diagnoses, while food allergy, viral skin infections and eczema were more common in genetically undiagnosed patients. These findings support the clinical value of targeted gene panels as an effective, accessible and informative tool in the diagnosis and classification of PIDDs, enhancing precision in patient care and enabling tailored therapeutic strategies.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"101 6","pages":"e70031"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Obesity on Treatment Response in Patients With Chronic Inflammatory Disease Receiving Biologic Therapy: Secondary Analysis of the Prospective Multicentre BELIEVE Cohort Study.","authors":"Klara Riber Eggers, Karen Mai Møllegaard, Laura Gregersen, Silja Hvid Overgaard, Zainab Hikmat, Torkell Ellingsen, Jens Kjeldsen, Andreas Kristian Pedersen, Sofie Ronja Petersen, Mohamad Jawhara, Anders Bathum Nexøe, Anette Bygum, Christian Lodberg Hvas, Jens Frederik Dahlerup, Frederik Olof Bergenheim, Henning Glerup, Jacob Broder Brodersen, Heidi Lausten Munk, Natalia Pedersen, Ole Haagen Nielsen, Karina Winther Andersen, Berit Lillenthal Heitmann, Robin Christensen, Vibeke Andersen","doi":"10.1111/sji.70035","DOIUrl":"10.1111/sji.70035","url":null,"abstract":"<p><p>Biological therapy is used to treat chronic inflammatory diseases (CIDs); however, up to 50% of patients fail to achieve an adequate clinical response. This study aimed to access the impact of obesity on clinical treatment response in CID patients after 14-16 weeks of biological therapy. This multicentre prospective cohort study enrolled 233 adults between 2017 and 2020 diagnosed with Crohn disease, ulcerative colitis (UC), rheumatoid arthritis, axial spondyloarthritis (PsA), psoriatic arthritis or psoriasis scheduled for biologic therapy. The main analysis population included patients with BMI data before treatment initiation, categorising patients as either obese (BMI ≥ 30 kg/m²) or non-obese (BMI < 30 kg/m²). The primary endpoint was the proportion of patients achieving clinical treatment response after 14-16 weeks. Main analyses were based on logistic regression with a factor for obesity, while adjusted for sex and age. Of the 228 patients eligible for the main analyses, 125 (55%) responded to biologic therapy. In the obese group (n = 59), 30 (51%) patients responded compared to the 95 (56%) individuals categorised as non-obese (n = 169), with no difference between groups (OR: 0.82, 95% CI: 0.43 to 1.60). This study did not find a lower likelihood of response to biologics in obese individuals compared with non-obese counterparts. Trial Registration: ClinicalTrials.gov identifier: NCT03173144.</p>","PeriodicalId":21493,"journal":{"name":"Scandinavian Journal of Immunology","volume":"101 6","pages":"e70035"},"PeriodicalIF":4.1,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183491/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144369185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}